The effects of calcitonin on lipid metabolism were investigated in three kinds of rats, one strain of rabbits, and a primary culture of rat hepatocytes. 
Introduction
Factors affecting lipid metabolism are usually classified as exogenous or endogenous. Exogenous factors include dietary factors, exercise, and iatrogenic factors. Endogenous factors include genetic factors and enzyme or hormonal disturbances. Ofthe hormones, especially peptide hormones, that affect lipid metabolism, insulin, glucagon, gonadotropin, growth hormone, adrenocorticotropic hormone, and so on, are known to have physiological or pharmacological significance. It has come to be believed that PTH and calcitonin may also participate in lipid metabolism.
PTH stimulates lipolysis in vitro (1, 2) and in vivo (3) and elevates the level of cholesterol in experimental animals (4, 5) . Parathyroidectomy decreases the level of cholesterol in patients with chronic renal disease (6, 7) . These studies suggest that PTH affects lipid metabolism. Calcitonin gene-related peptide (CGRP),' which is biosynthesized by alterations in the Address reprint requests to Dr. Yoshiki Nishizawa, Second Department of Internal Medicine, Osaka City University Medical School, 1-5-7, Asahi-machi, Abeno-ku, Osaka 545, Japan.
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1. Abbreviations used in this paper: CGRP, calcitonin gene-related peptide; CM, chylomicrons; Pi, inorganic phosphate; PI, phosphatidyinositol; VMH, ventromedial hypothalamus; W5, N-(6-aminohexyl)-1-naphthalenesulfonamide; W7, N46-aminohexyl)-5-chloro-1-naphthalenesulfonamide/HCI.
processing of RNA transcripts from the calcitonin gene, seems to resemble calcitonin in its action. However, CGRP is not identical to calcitonin in either its action or receptor sites (8) (9) (10) . There are contradictory reports about the liver receptor for CGRP. One group found specific binding in liver (1 1), another did not (12) . The effect of CGRP on lipid metabolism has been speculated upon, but not clearly identified. Calcitonin inhibits the lipolysis induced by PTH in rat epididymal adipose tissues (13) . Calcitonin causes glycogenolysis and affects amino acid metabolism in the liver (14, 15) , and also affects the metabolism of calcium and phosphate (16) (17) (18) .
Zucker rats with genetic obesity have a high concentration of calcitonin in their serum (19) and pituitary (20) . These animals are also hyperlipoproteinemic (21) , so calcitonin might have a pathophysiological significance in the disordered lipid metabolism of these rats. These results suggest the possibility that calcitonin is involved in lipid metabolism. Together, the findings indicate that calcitonin affects lipid metabolism. In the in vivo part of this study, four experimental models of hyperlipidemia were examined to check the effect of calcitonin administration on the serum level of lipids. In the in vitro part of the study, a primary culture of rat hepatocytes was used to investigate the effect of calcitonin on lipogenesis in the liver.
Methods

General protocol
In vivo study. The effect of calcitonin injections on lipid levels was evaluated in (a) rats fed a high-fat diet, (b) uremic rats, (c) rats after the destruction of the ventromedial hypothalamus (VMH rats), which caused hypothalamic obesity, and (d) Watanabe- 
R )~~~~~-at the dose of 250 and 1,000 mU/kg body wt, respectively. Blood was sampled before the injection and at 2, 4, and 24 h after each injection in weeks 1, 8, and 12.
Hepatocyte isolation and monolayer culture. Parenchymal hepatocytes were isolated from male Sprague-Dawley rats that had been given regular chow ad lib. The cells were isolated by in situ perfusion of the liver with collagenase (26) . They were suspended at 5 X I05 cells/ml in William's medium E, containing 10% FCS, 10-5 M dexamethasone, and 2 X 10-9 M insulin, and cultured at the density of 105 cells/cm2 in plastic dishes (Falcon Labware, Becton, Dickinson & Co., Oxnard, CA) in a humidified chamber at 370C under 5% CO2 and 30% 02 in the air. Cell viability was usually > 90% as measured by a trypan blue exclusion test. After culture for 6 h, the medium was changed; it was changed daily thereafter.
Assay oflipogenesis. Monolayers of hepatocytes in 35-mm dishes were incubated with 1.5 ml of Hanks' solution containing 5 mM Hepes, 5 mM sodium [1-14C] Study ofcalmodulin inhibitor. For some of the rats on the high-fat diet, N-(6-aminohexyl)-5-chloro-l-naphthalenesulfonamide/HCl (W7) was injected intraperitoneally 1 h before an injection of calcitonin at the dose of 1 mg/rat. In the study of hepatocytes, W7 was added to the concentration of 5-10 AM 1 h before the addition of calcitonin. N-(6-Aminohexyl)-l-naphthalenesulfonamide (W5) is a drug with less calmodulin-antagonizing effect than W7 but with the same cytotoxicity. W7 The results are expressed as means±SE. They were analyzed by use of the unpaired t test for evaluation of the significance compared with controls and by multiple comparison (Scheffe type). Significance of dose relationships, time relationships, and the interaction of drugs was calculated by analysis of variance.
Results
Effect ofcalcitonin on serum levels oflipids. In rats on a highfat diet, a single injection of calcitonin at the dose of 1,000 mU/rat decreased the serum cholesterol level. The same tendency was true for serum triglycerides. Lipoproteins were also significantly decreased by this treatment (Fig. 1 A) . With 250 mU/rat, cholesterol had decreased significantly compared with the control by 2 h after the injection. The decrease at this time with 4,000 mU/rat also was significant. With 250 mU/rat, triglycerides tended to decrease at 2 h (Fig. 1 B) . These findings indicated that a single injection of calcitonin at the dose of Values were by triplicate assays. CT, calcitonin.
1,000 mU/rat decreased the serum level of lipids measured 2 h later. Calcitonin after one injection into control rats or rats on the high-fat diet had the effects shown in Fig. 2 . The long-term effect of calcitonin was investigated by use of multiple injections in experimental animals. Regular injections of calcitonin for 12 wk significantly decreased the levels of cholesterol (P < 0.05) and triglycerides (P < 0.01) to the daily dose of 50 mU/rat in the uremic rats (Table I ). The calcitonin did not affect the food intake or body weight in VMH rats, in which cholesterol and triglycerides in serum decreased when the dose of 50 mU/kg body wt was injected three times weekly for 4 wk (P < 0.025 and < 0.01, respectively; Table II ). Calcitonin decreased LDL for 24 h in the WHHL rabbit given one dose of 250 or 1,000 mU/kg, and the same effect was seen with three injections a week, because LDL was lower at weeks 8 and 12 than at the baseline levels (Fig. 3) .
Effect of W7 on the decrease of lipids by calcitonin. The injection of W7 1 h before the injection of calcitonin did not inhibit the decreases in FFA and chylomicrons (CM), but did prevent the decreases in both LDL and triglycerides (Table  III) . These findings suggested that W7 suppressed the action of calcitonin and that its suppression was somehow concerned with the calcium/calmodulin mechanism.
Effect of calcitonin on lipogenesis in the rat hepatocytes. The incorporation of ['4C]acetate into cholesterol was reduced by the addition of calcitonin in a dose-dependent way at 60 and 120 min (Fig. 4 A) . The incorporation of [14C]acetate into triglycerides was inhibited in the same way (Fig. 4 B) , as was the incorporation of ['4C]acetate into FFA and cholesterol ester (Fig. 4 C) . The findings showed that calcitonin suppressed the synthesis of lipids in hepatocytes.
Effect of calcitonin on intracellular cAMP levels. 10-9 M glucagon increased cAMP in the hepatocytes measured at 3 min, and gave more than three times that value when 10 mM theophylline was present. Calcitonin alone at 2.94 X 10-' M did not increase cAMP, nor did it do so when theophylline was present (Fig. 5 A) . The level ofcAMP was monitored for up to 20 min ofincubation, but calcitonin did not increase it with or without theophylline (Fig. 5 B) .
Effect of calcitonin on PI turnover. Vasopressin increased the incorporation of [32P]Pi into PI at 4.71 X 10-7 M for 60 min (P < 0.01), but calcitonin did not increase the incorporation at either 3.85 X 10-6 or 3.85 X l0-' M (9,623±428 cpm/ mg protein for the vehicle, 9,188±542 cpm/mg protein for 3.85 X 10-6 M calcitonin, 11,307±566 cpm/mg protein for 3 (Fig. 6 ). The inhibition caused by calcitonin of such incorporation into cholesterol and into triglycerides was exactly the same, so the difference between the lipogenesis in medium with 1.2 mM calcium and that in calcium-free me- (Fig. 7 A) . There was no significant interaction between calcitonin and W7 in the synthesis ofcholesterol. Figure 6 . Effect of calcium ion in the medium on lipogenesis of rat hepatocytes in the presence or absence of calcitonin. *P < 0.05 and **P < 0.025 compared with the control by t test. Values were by triplicate assays. and W7 in the synthesis of triglycerides from acetate and from palmitate ( Fig. 7 B and Fig. 8 ).
Discussion
These experiments examined the effects of calcitonin on lipid metabolism. The in vivo experiments showed that calcitonin decreased serum cholesterol and triglycerides, which are the main components of LDL and VLDL, respectively, in models of hyperlipidemia caused by different mechanisms in experimental animals: uremic rats, hypothalamic obese rats, rats on a high-fat diet, and WHHL rabbits. In the uremic rats, the main cause of hyperlipidemia is probably peripheral impairment ofthe removal of lipids from the blood, possibly because of the lowered metabolic turnover of VLDL caused by the suppression of lipoprotein lipase (29, 30) , abnormalities in the protein parts of the lipoproteins (31), and decreased hepatic lipase (32) . In the hypothalamic obese rats, hyperlipidemia arises from hyperinsulinemia because of decreased activity of the sympathetic nerve and increased activity of the vagus nerve after the destruction of the ventromedial nucleus of the hypothalamus, which induces hyperphagia, increased lipogenesis, and suppressed lipolysis (33) (34) (35) . A high-fat diet consisting of 60% fat causes obesity and hyperlipidemia because of the increased exogenous lipids and increased lipogenesis without hyperinsulinemia (36, 37) . In the WHHL rabbits, removal of LDL from the blood is disturbed because of the genetic deficit of LDL receptors (38, 39) .
For uremic rats, there are two possible explanations for the calcitonin-induced hypolipidemic effect. Calcitonin may facilitate the removal of lipids peripherally, and it may inhibit lipogenesis. The first reason is a likely one, because calcitonin is effective within 1 or 2 h in rats on a high-fat diet. That calcitonin decreases LDL in WHHL rabbits suggests that the effect is mediated by a pathway independent of LDL receptors.
The second reason is also likely because calcitonin is effective in VMH rats with hyperlipidemia mainly caused by increased lipogenesis. In the rats on the high-fat diet, treatment with W7 did not block the effects of calcitonin on CM and FFA, but it did block the effect on LDL and VLDL. There should be at least two different mechanisms for the hypolipidemic effect by calcitonin, one in which W7 has no effect, and a calcium/calmodulin-dependent mechanism. Calcitonin has cAMP-dependent effects on bone resorption in the rat (40) , the transport of calcium in the thick ascending-limb renal tubules of rabbits (41), and the reabsorption ofcalcium in the cortical thick ascending limb ofHenle or distal segment ofrat kidney, as do both PTH and glucagon (42, 43) . Calcitonin has also been found to have antilipolytic effects in slices ofrat fat pad at basal levels or levels slightly stimulated by PTH, noradrenaline, or dibutyryl cAMP; these effects of calcitonin are mediated by a cAMP-dependent mechanism (13) . FFA was decreased by calcitonin, and the mechanism of the lipolytic action did not involve the calcium/calmodulinmediated system here, which demonstrates that calcitonin has a cAMP-dependent effect on lipolysis. However ( 12, 46) . In our in vitro study, we focused on the effect of calcitonin on lipogenesis in hepatocytes to examine the calcium/calmodulin-mediated mechanism of calcitonin, especially in the esterification of triglycerides. No evidence was found in these cells of a cAMP-dependent pathway or of any association of the hypolipidemic effect of calcitonin with PI turnover.
Calcitonin accelerates glucose production in the liver (14) , which may decrease the amount of substrate such as pyruvate and acetyl Co A for fatty acid synthesis; the decreased amount of substrates probably results in the suppressed synthesis of fatty acids. Calcitonin also promotes the conversion ofalanine to pyruvate (47) , probably by the direct, calmodulin-independent action of calcium ion, so increased gluconeogenesis is one possible mechanism for the decrease in triglycerides caused by calcitonin, although not the major mechanism.
Calcium has many biological effects on the permeability of membranes by ions, promotion of enzyme activity, control of microtubules, secretion of hormones, and other effects in muscle cells and neurons (48) . In kidney or liver cells, a transient but rapid influx of calcium into the cell occurs when the cell is stimulated by an appropriate hormone, such as glucagon or PTH (48) . Calcitonin inhibits the outflow of calcium from bone (49) , kidney (50) , and liver cells (14) . An outflow of calcium is, in general, involved with the activity of calciumATPase, which is lowered by calcitonin. Calcitonin presumably increases the intracellular concentration of calcium ion. In this study, we considered two kinds of inhibition of lipogenesis caused by calcitonin in the hepatocytes, that which is dependent on calcium ion in the medium and that which is independent of it. In the former, calcitonin works with extracellular calcium ion to inhibit lipogenesis, and in the latter, calcitonin rearranges the intracellular shift of calcium ion. Inaba et al. (51) have reported that calcitonin stimulates phosphorylation of two liver cytosolic proteins with molecular weights of 67,000 and 93,000. Stimulation of phosphoiylation ofthe 93,000Mr protein by calcitonin depends on calcium ion but not on cAMP, and is inhibited by W7. The study suggested that there is a calcium/calmodulin-mediated mechanism induced by calcitonin in the liver. In this study, we confirmed that the concentration of calcium in the medium is associated with lipogenesis caused by calcitonin and that calmodulin inhibitor blocks this effect, so the effect of calcitonin may be mediated by a calcium/calmodulin pathway. Calcitonin probably suppresses lipogenesis in the hepatocytes directly through the increase in intracellular calcium, the increased influx and decreased efflux of calcium, and the intracellular shift from mitochondria to the cytosol, which may shift intracellular calcium-binding protein, calmodulin, and other calcium-binding proteins without changes in cAMP or the PI turnover.
Endocytosis of lipids and lipoproteins and calcium mineralization occur in the final stage ofthe formation ofatherosclerotic plaques (52, 53) . Several calcium ion antagonists suppress experimental atherogenesis (54) (55) (56) . In addition to other calcium-related agents like Mg-EDTA (57), chondroitin sulfate A (58), and reserpine (59) , calcitonin (60) could be a candidate for use as an antiatherogenic drug.
